By InvitationPhase 3

Intravitreal and Intracameral DEX in NPDR

China80 participantsStarted 2022-01-31

Plain-language summary

To investigate the effects of intravitreal and intracameral injection of dexamethasone during cataract phacoemulsification in patients with mild to moderate non-proliferative diabetic retinopathy

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: type 2 diabetic cataracts patients who were diagnosed with mild to moderate NPDR Exclusion Criteria: \-

What they're measuring

measure the central point thickness (CPT) and central foveal thickness (CFT)

Timeframe: From enrollment to the end of treatment at 3 months

Trial details

NCT IDNCT06951087

SponsorAffiliated Hospital of Nantong University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-04-20

View on ClinicalTrials.gov More Non-Proliferative Diabetic Retinopathy trials